Serum aldo-keto reductase family 1 member B10 predicts advanced liver fibrosis and fatal complications of nonalcoholic steatohepatitis.
Adult
Aged
Aged, 80 and over
Aldo-Keto Reductases
/ blood
Biomarkers
/ blood
Carcinoma, Hepatocellular
/ blood
Disease Progression
Female
Humans
Liver Cirrhosis
/ blood
Liver Neoplasms
/ blood
Male
Middle Aged
Non-alcoholic Fatty Liver Disease
/ blood
Plant Lectins
/ analysis
Prognosis
Receptors, N-Acetylglucosamine
/ analysis
Aldo–keto reductase family 1 member B10
Nonalcoholic steatohepatitis
Wisteria floribunda agglutinin-positive Mac-2 binding protein
Journal
Journal of gastroenterology
ISSN: 1435-5922
Titre abrégé: J Gastroenterol
Pays: Japan
ID NLM: 9430794
Informations de publication
Date de publication:
Jun 2019
Jun 2019
Historique:
received:
31
07
2018
accepted:
19
01
2019
pubmed:
2
2
2019
medline:
20
6
2020
entrez:
2
2
2019
Statut:
ppublish
Résumé
Nonalcoholic steatohepatitis (NASH) is associated with liver inflammation in patients with nonalcoholic fatty liver disease, and it can progress to liver fibrosis at an advanced stage, as well as hepatocellular carcinoma (HCC) and portal hypertension. Although liver fibrosis is accurately diagnosed via biopsy, noninvasive methods are preferable. Aldo-keto reductase family 1 member B10 (AKR1B10) is associated with HCC and is secreted into the blood by liver cells via a lysosome-mediated nonclassical pathway. Accordingly, we analyzed whether secretion of AKR1B10 protein is associated with advanced NASH. We performed histological staging in 85 Matteoni classification type III and IV NASH patients and evaluated the incidence of HCC, formation of gastroesophageal varices, and prognosis according to serum AKR1B10 and Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA(+)-M2BP)(M2BPGi) and by comparison with conventional markers of fibrosis. A positive correlation was found between the Brunt classification and serum AKR1B10 level. In Brunt stage 4 patients, AKR1B10 levels were higher than those of other liver fibrosis markers, with higher specificity. The cutoff values for AKR1B10 and WFA(+)-M2BP for stage 4 fibrosis were 1.03 and 3.11, respectively. The rates of stage 4 fibrosis, HCC incidence, and gastroesophageal varix formation were significantly different between the two groups subdivided according to these cutoff levels. Moreover, the patients in the higher value group had significantly worse prognosis after NASH diagnosis CONCLUSION: AKR1B10 is a useful serum biomarker for advanced liver fibrosis in NASH and, combined with serum WFA(+)-M2BP, can predict HCC development, gastroesophageal varix formation, and poor prognosis.
Sections du résumé
BACKGROUND
BACKGROUND
Nonalcoholic steatohepatitis (NASH) is associated with liver inflammation in patients with nonalcoholic fatty liver disease, and it can progress to liver fibrosis at an advanced stage, as well as hepatocellular carcinoma (HCC) and portal hypertension. Although liver fibrosis is accurately diagnosed via biopsy, noninvasive methods are preferable. Aldo-keto reductase family 1 member B10 (AKR1B10) is associated with HCC and is secreted into the blood by liver cells via a lysosome-mediated nonclassical pathway. Accordingly, we analyzed whether secretion of AKR1B10 protein is associated with advanced NASH.
METHODS
METHODS
We performed histological staging in 85 Matteoni classification type III and IV NASH patients and evaluated the incidence of HCC, formation of gastroesophageal varices, and prognosis according to serum AKR1B10 and Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA(+)-M2BP)(M2BPGi) and by comparison with conventional markers of fibrosis.
RESULTS
RESULTS
A positive correlation was found between the Brunt classification and serum AKR1B10 level. In Brunt stage 4 patients, AKR1B10 levels were higher than those of other liver fibrosis markers, with higher specificity. The cutoff values for AKR1B10 and WFA(+)-M2BP for stage 4 fibrosis were 1.03 and 3.11, respectively. The rates of stage 4 fibrosis, HCC incidence, and gastroesophageal varix formation were significantly different between the two groups subdivided according to these cutoff levels. Moreover, the patients in the higher value group had significantly worse prognosis after NASH diagnosis CONCLUSION: AKR1B10 is a useful serum biomarker for advanced liver fibrosis in NASH and, combined with serum WFA(+)-M2BP, can predict HCC development, gastroesophageal varix formation, and poor prognosis.
Identifiants
pubmed: 30707282
doi: 10.1007/s00535-019-01551-3
pii: 10.1007/s00535-019-01551-3
doi:
Substances chimiques
Biomarkers
0
Plant Lectins
0
Receptors, N-Acetylglucosamine
0
wisteria lectin
0
AKR1B10 protein, human
EC 1.1.1.-
Aldo-Keto Reductases
EC 1.1.1.-
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
549-557Références
Am J Gastroenterol. 1999 Sep;94(9):2467-74
pubmed: 10484010
Arterioscler Thromb Vasc Biol. 2003 Jul 1;23(7):1262-8
pubmed: 12750120
Clin Cancer Res. 2005 Mar 1;11(5):1776-85
pubmed: 15755999
Hepatology. 2007 Apr;45(4):846-54
pubmed: 17393509
Hepatology. 2008 Feb;47(2):484-92
pubmed: 18220286
Gut. 2008 Oct;57(10):1441-7
pubmed: 18390575
Nat Genet. 2008 Dec;40(12):1461-5
pubmed: 18820647
J Hepatol. 2010 Feb;52(2):220-7
pubmed: 20036025
J Gastroenterol. 2011 Feb;46(2):257-68
pubmed: 20842510
Hepatology. 2010 Nov;52(5):1836-46
pubmed: 21038418
Cancer Cell. 2011 Oct 18;20(4):511-23
pubmed: 22014576
BMC Gastroenterol. 2012 Jan 05;12:2
pubmed: 22221544
Mod Pathol. 2012 May;25(5):758-66
pubmed: 22222635
Int J Cancer. 2012 Sep 15;131(6):E862-71
pubmed: 22539036
PLoS One. 2012;7(10):e46584
pubmed: 23071592
J Gastroenterol. 2013 Sep;48(9):1051-60
pubmed: 23184095
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
J Biol Chem. 2013 Dec 20;288(51):36733-40
pubmed: 24217247
Hepatology. 2014 Nov;60(5):1563-70
pubmed: 25042054
J Gastroenterol. 2015 Jul;50(7):776-84
pubmed: 25326152
Am J Gastroenterol. 2015 Jun;110(6):857-64
pubmed: 25916223
Gastroenterology. 2015 Aug;149(2):389-97.e10
pubmed: 25935633
Expert Rev Proteomics. 2015;12(6):683-93
pubmed: 26394846
Hepatol Res. 2016 May;46(6):575-83
pubmed: 26418076
Hepatology. 2016 Jul;64(1):73-84
pubmed: 26707365
Hepatol Res. 2016 Nov;46(12):1194-1202
pubmed: 26836229
Sci Rep. 2016 Mar 31;6:23279
pubmed: 27029598
Clin Liver Dis. 2016 May;20(2):205-14
pubmed: 27063264
J Gastroenterol Hepatol. 2017 Dec;32(12):1922-1930
pubmed: 28406534
J Gastroenterol. 2018 Jan;53(1):129-139
pubmed: 28589339
J Gastroenterol. 2018 Jun;53(6):740-751
pubmed: 28849280
Hepatol Res. 2018 Jun;48(7):521-528
pubmed: 29316028
J Gastroenterol. 2018 Jul;53(7):819-826
pubmed: 29318378
J Dig Dis. 2018 Apr;19(4):242-253
pubmed: 29607614
J Gastroenterol. 2018 Nov;53(11):1216-1224
pubmed: 29744597
J Hepatol. 2018 Oct;69(4):878-885
pubmed: 29802949
Hepatol Res. 2018 Dec;48(13):1099-1107
pubmed: 29974624
Hepatology. 2019 Mar;69(3):1075-1086
pubmed: 30014517
J Biol Chem. 1998 May 8;273(19):11429-35
pubmed: 9565553